Caris Life Sciences, Inc. (CAI) stock
Close on Nov 12, 2026Market cap $6.77BP/E –Yield –
Caris Life Sciences, Inc. grew revenue 61.5% to $1.05B over the twelve months to Sep 30, 2026. Free cash flow was $28.91M. At the latest close the market valued the company at $6.77B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $6.77B
- P/E ratio
- –
- Price to sales
- 6.46
- Price to book
- 10.59
- Dividend yield
- –
- Free cash flow yield
- 0.43%
Fundamentals
- Revenue
- $1.05B
- Net income
- $96.06M
- EPS, diluted
- -$3.22
- Free cash flow
- $28.91M
- Book value per share
- $2.17
- Diluted shares
- 295M
Trading
- Next earnings
- Feb 25, 2027 (estimated, during market hours)
- Previous close
- $24.49
- Open
- $23.66
- Day's range
- $23.05 – $24.32
- Volume
- 3,571,760
- Average volume (20 days)
- 3,940,856
- Index membership
- Russell 1000 (since Sep 2025), Russell 3000 (since Aug 2025)
- 52-week range
- $14.19 – $36.50
- RSI (14 days)
- 32.8
- Volatility (1 year)
- 69.6%
- Relative volume
- 0.77×
Index membership is inferred from the holdings of funds that track each index (IWB, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | CAI | S&P 500 | Difference | CAI per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -19.3% | -2.7% | −16.6 pts | ||
| 3 months | +7.6% | -1.7% | +9.4 pts | ||
| Year to date | -11.2% | +11.9% | −23.1 pts | ||
| 1 year | -3.3% | +12.0% | −15.3 pts |
Four years at a glance
Fiscal years 2022 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Caris Life Sciences filed with the SEC as exhibits to Form 8-K or 6-K
About Caris Life Sciences
Services-Medical Laboratories
Caris is a precision medicine and biotechnology enterprise that develops and commercializes artificial intelligence-powered molecular profiling solutions focused primarily on oncology. Its offerings span the cancer care continuum, including early detection, minimal residual disease tracking, therapy selection, and treatment monitoring, as well as drug target discovery. The core product lines include the MI Profile platform for tissue-based whole exome and whole transcriptome sequencing, the Caris Assure platform for blood-based profiling, and the Precision Whole Genome platform. Caris serves clinical, academic, and biopharmaceutical markets, delivering molecular reports to treating oncologists while collaborating with biopharma companies and academic centers on biomarker research and therapeutic pipelines.
Company profile, executives and historyCaris Life Sciences stock: common questions
What is Caris Life Sciences's stock price?
CAI closed at $23.96 on Nov 12, 2026, down 2.16% on the day. Over the past 52 weeks it traded between $14.19 and $36.50.
What is Caris Life Sciences's market cap?
Caris Life Sciences was worth $6.77B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is CAI's P/E ratio?
Caris Life Sciences lost money over fiscal 2025 (diluted EPS -$3.22), so it has no meaningful P/E ratio.
How much revenue does Caris Life Sciences make?
Caris Life Sciences reported revenue of $1.05B for the twelve months to Sep 30, 2026, up 61.5% from a year earlier.
Does Caris Life Sciences pay a dividend?
No. Caris Life Sciences has not paid a cash dividend over the last twelve months.
When does Caris Life Sciences report earnings next?
Caris Life Sciences is expected to report Q4 FY2026 results on Feb 25, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has CAI stock performed over the past year?
Including dividends, CAI returned -3.3% over the past year, against +12.0% for the S&P 500.
How many CAI shares are sold short?
11M shares were sold short at the latest FINRA report, 11.33% of the float, or 4.0 days of average trading volume.
Who are Caris Life Sciences's competitors?
Companies most similar to Caris Life Sciences by business, industry and size include GH, BNR, NTRA, VCYT, CSTL.
See a number that looks wrong?